United States Aminoglycosides Market Size, Share, and COVID-19 Impact Analysis, By Product (Neomycin, Tobramycin, Gentamicin, Amikacin, Paromomycin, Streptomycin, Kanamycin, and Others), By Route of Administration (Injectables, Feed, Intra-mammary, Topical, and Oral), and United States Aminoglycosides Market Insights, Industry Trend, Forecasts to 2035

United States Aminoglycosides Market Insights Forecasts to 2035

• The US Aminoglycosides Market Size Was Estimated at USD 630.6 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 4.39% from 2025 to 2035
• The US Aminoglycosides Market Size is Expected to Reach USD 1011.2 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the United States Aminoglycosides Market Size is Anticipated to Reach USD 1011.2 Million by 2035, Growing at a CAGR of 4.39% from 2025 to 2035. The expansion of the United States aminoglycosides market is propelled by the increasing prevalence of gram-positive and gram-negative bacterial infections.

Market Overview

Aminoglycosides are a class of potent antibiotics composed of amino sugar molecules joined to a core hexose nucleus. As a result of governments providing essential antibiotics through national health programs or subsidised systems, the market is growing through the promoted use of aminoglycosides for an array of infectious diseases. One critical component of the treatment for bronchial disorders involves the formulation of inhalation for intravenous administration, which adds to market growth for aminoglycosides. The newer technological advancements in devices for administering medications allow for more efficient utilization of these drugs in medicine. Several programmes provided by organisations increase access to antibiotics in areas with limited resources, leading to increased use. Aminoglycoside use is being driven up due to the urgent demand for advanced antibiotic solutions because of the emergence of communicable and multidrug-resistant bacterial strains. The development of next-generation aminoglycosides, like plazomicin, is an important step in the battle against highly resistant gram-negative bacteria. This provides a chance for newer antibiotics to be more successful when utilized, but also provides pharmaceutical companies with new opportunities.

Report Coverage

This research report categorizes the market for the United States aminoglycosides market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States aminoglycosides market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United States aminoglycosides market.

Driving Factors

The growth of the United States aminoglycosides market is boosted by the increasing incidence of multidrug-resistant gram-negative infections, particularly in hospitals, necessitating the use of medications like amikacin and gentamicin in severe situations, such as ventilator-associated pneumonia and sepsis. Hospital-based use is also driven by an ageing population that is more susceptible to infections and more surgeries. Furthermore, improvements in drug formulations and delivery methods, like liposomal, nanoparticle, or inhalation technologies, increase safety and effectiveness and expand the range of applications.

Restraining Factors

The United States aminoglycosides market faces obstacles like dose-dependent toxicities that restrict prescribing in susceptible groups, such as the elderly individual with kidney illness, and necessitate strict therapeutic drug monitoring, including nephrotoxicity and persistent ototoxicity.

Market Segmentation

The United States aminoglycosides market share is classified into product and route of administration.

• The gentamicin segment held the largest market share in 2024 and is expected to grow at a remarkable CAGR during the forecast period.

The United States aminoglycosides market is segmented by product into neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, kanamycin, and others. Among these, the gentamicin segment held the largest market share in 2024 and is expected to grow at a remarkable CAGR during the forecast period. The segment is driven because it has grown considerably, and new approaches with better efficacy, delivery, and tolerability mean it’s are improving patient care. Effective use of gentamicin topically could also be a useful way to treat genodermatosis from nonsense mutations, particularly as it is cost-effective and has low toxicity.

• The injectables segment held the highest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

Based on the route of administration, the United States aminoglycosides market is segmented into injectables, feed, intra-mammary, topical, and oral. Among these, the injectables segment held the highest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is propelled by individuals suffering from severe or acute infections typically want to receive injectable medications that can rapidly treat their clinical infection. A new intravenous (IV) aminoglycoside antibiotic called plazomicin is indicated for pyelonephritis and other complex urinary tract infections.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States aminoglycosides market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Viatris Inc
• Merck & Co., Inc.
• AbbVie Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Cipla Limited
• Lupin Limited
• Aurobindo Pharma
• Others

Recent Development

• In July 2023, Harrow Health, a U.S. eyecare pharmaceutical company, expanded its portfolio by acquiring certain U.S. and Canadian commercial rights from Santen Pharmaceutical Co., Ltd. This acquisition includes TOBRADEX ST (tobramycin and dexamethasone ophthalmic suspension).

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United States, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United States aminoglycosides market based on the following segments:

United States Aminoglycosides Market, By Product

• Neomycin
• Tobramycin
• Gentamicin
• Amikacin
• Paromomycin
• Streptomycin
• Kanamycin
• Others

United States Aminoglycosides Market, By Route of Administration

• Injectables
• Feed
• Intra-mammary
• Topical
• Oral